Laura C Gioia1, Mahesh Kate1, Leka Sivakumar1, Dulara Hussain1, Hayrapet Kalashyan1, Brian Buck1, Miguel Bussiere1, Thomas Jeerakathil1, Ashfaq Shuaib1, Derek Emery1, Ken Butcher2. 1. From the Division of Neurology, University of Montreal, Montreal, Canada (L.C.G.); and Division of Neurology (M.K., L.S., D.H., H.K., B.B., M.B., T.J., A.S., K.B.), and Department of Diagnostic Imaging (D.E.), University of Alberta, Alberta, Canada. 2. From the Division of Neurology, University of Montreal, Montreal, Canada (L.C.G.); and Division of Neurology (M.K., L.S., D.H., H.K., B.B., M.B., T.J., A.S., K.B.), and Department of Diagnostic Imaging (D.E.), University of Alberta, Alberta, Canada. ken.butcher@ualberta.ca.
Abstract
BACKGROUND AND PURPOSE: Early anticoagulation after cardioembolic stroke remains controversial because of the potential for hemorrhagic transformation (HT). We tested the safety and feasibility of initiating rivaroxaban ≤14 days after cardioembolic stroke/transient ischemic attack. METHODS: A prospective, open-label study of patients with atrial fibrillation treated with rivaroxaban ≤14 days of transient ischemic attack or ischemic stroke (National Institute of Health Stroke Scale <9). All patients underwent magnetic resonance imaging <24 hours of rivaroxaban initiation and day 7. The primary end point was symptomatic HT at day 7. RESULTS: Sixty patients (mean±SD age 71±19 years, 82% stroke/18% transient ischemic attack) were enrolled. Median (interquartile range) time from onset to rivaroxaban was 3 (5) days. At treatment initiation, median National Institute of Health Stroke Scale was 2 (4), and median diffusion-weighted imaging volume was 7.9 (13.7) mL. At baseline, HT was present in 25 (42%) patients (hemorrhagic infarct [HI]1=19, HI2=6). On follow-up magnetic resonance imaging, no patients developed symptomatic HT. New asymptomatic HI1 developed in 3 patients, and asymptomatic progression from HI1 to HI2 occurred in 5 patients; otherwise, HT remained unchanged at day 7. CONCLUSIONS: These data support the safety of rivaroxaban initiation ≤14 days of mild-moderate cardioembolic stroke/transient ischemic attack. Magnetic resonance imaging evidence of petechial HT, which is common, does not appear to increase the risk of symptomatic HT.
BACKGROUND AND PURPOSE: Early anticoagulation after cardioembolic stroke remains controversial because of the potential for hemorrhagic transformation (HT). We tested the safety and feasibility of initiating rivaroxaban ≤14 days after cardioembolic stroke/transient ischemic attack. METHODS: A prospective, open-label study of patients with atrial fibrillation treated with rivaroxaban ≤14 days of transient ischemic attack or ischemic stroke (National Institute of Health Stroke Scale <9). All patients underwent magnetic resonance imaging <24 hours of rivaroxaban initiation and day 7. The primary end point was symptomatic HT at day 7. RESULTS: Sixty patients (mean±SD age 71±19 years, 82% stroke/18% transient ischemic attack) were enrolled. Median (interquartile range) time from onset to rivaroxaban was 3 (5) days. At treatment initiation, median National Institute of Health Stroke Scale was 2 (4), and median diffusion-weighted imaging volume was 7.9 (13.7) mL. At baseline, HT was present in 25 (42%) patients (hemorrhagic infarct [HI]1=19, HI2=6). On follow-up magnetic resonance imaging, no patients developed symptomatic HT. New asymptomatic HI1 developed in 3 patients, and asymptomatic progression from HI1 to HI2 occurred in 5 patients; otherwise, HT remained unchanged at day 7. CONCLUSIONS: These data support the safety of rivaroxaban initiation ≤14 days of mild-moderate cardioembolic stroke/transient ischemic attack. Magnetic resonance imaging evidence of petechial HT, which is common, does not appear to increase the risk of symptomatic HT.
Authors: Jan C Purrucker; Kirsten Haas; Marcel Wolf; Timolaos Rizos; Shujah Khan; Peter Kraft; Sven Poli; Rainer Dziewas; Johannes Meyne; Frederick Palm; Sebastian Jander; Markus Möhlenbruch; Peter U Heuschmann; Roland Veltkamp Journal: J Stroke Date: 2017-01-31 Impact factor: 6.967
Authors: Irene Escudero-Martinez; Michael Mazya; Christine Teutsch; Norbert Lesko; Zuzana Gdovinova; Leonardo Barbarini; Waldemar Fryze; Michal Karlinski; Adam Kobayashi; Georgi Krastev; Ana Paiva Nunes; Katarina Pasztoova; André Peeters; Piotr Sobolewski; Aleksandras Vilionskis; Danilo Toni; Niaz Ahmed Journal: BMJ Open Date: 2020-05-19 Impact factor: 2.692
Authors: Duncan Wilson; Gareth Ambler; Gargi Banerjee; Clare Shakeshaft; Hannah Cohen; Tarek A Yousry; Rustam Al-Shahi Salman; Gregory Y H Lip; Henry Houlden; Martin M Brown; Keith W Muir; Hans Rolf Jäger; David J Werring Journal: J Neurol Neurosurg Psychiatry Date: 2018-11-19 Impact factor: 10.154
Authors: David Z Rose; John N Meriwether; Michael G Fradley; Swetha Renati; Ryan C Martin; Thomas Kasprowicz; Aarti Patel; Maxim Mokin; Ryan Murtagh; Kevin Kip; Andrea C Bozeman; Tara McTigue; Nicholas Hilker; Bonnie Kirby; Natasha Wick; Nhi Tran; W Scott Burgin; Arthur J Labovitz Journal: Front Neurol Date: 2019-09-20 Impact factor: 4.003